An important functional role of persistent Na+ current in carotid body hypoxia transduction.
Systemic hypoxia in mammals is sensed and transduced by the carotid body into increased action potential (AP) frequency on the sinus nerve, resulting in increased ventilation. The mechanism of hypoxia transduction is not resolved, but previous work suggested that fast Na(+) channels play an important role in determining the rate and timing of APs (Donnelly, DF, Panisello JM, and Boggs D. J Physiol. 511: 301-311, 1998). We speculated that Na(+) channel activity between APs, termed persistent Na(+) current (I(NaP)), is responsible for AP generation that and riluzole and phenytoin, which inhibit this current, would impair organ function. Using whole cell patch clamp recording of intact petrosal neurons with projections to the carotid body, we demonstrated that I(NaP) is present in chemoreceptor afferent neurons and is inhibited by riluzole. Furthermore, discharge frequencies of single-unit, chemoreceptor activity, in vitro, during normoxia (Po(2) 150 Torr) and during acute hypoxia (Po(2) 90 Torr) were significantly reduced by riluzole concentrations at or above 5 microM, and by phenytoin at 100 microM, without significant affect on nerve conduction time, AP magnitude (inferred from extracellular field), and AP duration. The effect of both drugs appeared solely postsynaptic because hypoxia-induced catecholamine release in the carotid body was not altered by either drug. The respiratory response of unanesthetized, unrestrained 2-wk-old rats to acute hypoxia (12% inspired O(2) fraction), which was measured with whole body plethysmography, was significantly reduced after treatment with riluzole (2 mg/kg ip) and phenytoin (20 mg/kg ip). We conclude that I(NaP) is present in chemoreceptor afferent neurons and serves an important role in peripheral chemoreceptor function and, hence, in the ventilatory response to hypoxia.
Faustino
Edward Vincent S
EV
Department of Pediatrics, Section of Critical Care and Applied Physiology, Yale University School of Medicine, 333 Cedar St., PO Box 208064, New Haven, CT 06520-8064, USA. vince.faustino@yale.edu
Donnelly
David F
DF
D000200:Action Potentials / Q000187:drug effects / Q000502:physiology; D000818:Animals; D002344:Carotid Body / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology*; D002395:Catecholamines / Q000378:metabolism; D002628:Chemoreceptor Cells / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D000860:Hypoxia / Q000503:physiopathology*; D066298:In Vitro Techniques; D008297:Male; D009620:Nodose Ganglion / Q000378:metabolism; D018408:Patch-Clamp Techniques; D010672:Phenytoin / Q000494:pharmacology; D010993:Plethysmography, Whole Body; D012123:Pulmonary Ventilation / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D019782:Riluzole / Q000494:pharmacology; D015398:Signal Transduction / Q000502:physiology*; D026941:Sodium Channel Blockers / Q000494:pharmacology; D015222:Sodium Channels / Q000187:drug effects / Q000378:metabolism*
D002395:Catecholamines; D026941:Sodium Channel Blockers; D015222:Sodium Channels; D010672:Phenytoin; D019782:Riluzole